Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling

Journal of the National Cancer Institute

Volumn 107, Issue 6, 2015, Pages

  Menendez, Javier A ^a   Schroeder, Barbara ^b,c   Peirce, Susan K ^d   Vellon, Luciano ^e   Papadimitropoulou, Adriana ^f   Espinoza, Ingrid ^b,g   Lupu, Ruth ^b,c  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d Kateric CRO   (United States)

^e INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^f HELLENIC PASTEUR INSTITUTE   (Greece)

^g UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL TRANSFORMATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DELETION MUTANT; DIMERIZATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIGAND BINDING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEADY STATE; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; BREAST; BREAST TUMOR; CELL LINE; DRUG EFFECTS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE; UPREGULATION; VIROLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DIMERIZATION; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; PACLITAXEL; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84930719545     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv090     Document Type: Article

References (71)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
2. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994;1198(2-3):165-184.
3. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl 1):S3-S8.
4. Menard S, Pupa SM, Campiglio M, et al. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22(42):6570-6578.
5. Arteaga CL. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? J Clin Oncol. 2006;24(23):3722-3725.
6. Choudhury A, Charo J, Parapuram SK, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer. 2004;108(1):71-77.
7. Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J Cell Biol. 2002;158(7):1239-1249.
8. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18(13):2241-2251.
9. Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429-440.
10. Carter P, Fendly BM, Lewis GD, et al. Development of herceptin. Breast Dis. 2000;11:103-111.
11. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285-4289.
12. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer. 2002;9(2):75-85.
13. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res. 2003;9(14):5078-5084.
14. A cross country comparison of exposure to secondhand smoke among youth. Tob Control. 2006;15(Suppl 2):ii4-ii19.
15. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232(2):123-138.
16. Harris NM, Anderson WR, Lwaleed BA, et al. Epirubicin and meglumine gamma-linolenic acid: A logical choice of combination therapy for patients with superficial bladder carcinoma. Cancer. 2003;97(1):71-78.
17. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3(6):385-389.
18. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61(Suppl 2):1-13.
19. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
20. Albanell J, Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst. 2001;93(24):1830-1832.
21. Badache A, Hynes NE. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell. 2004;5(4):299-301.
22. Bernard-Marty C, Cardoso F, Sotiriou C, et al. [Towards an individualization of systemic treatment of breast tumors]. Bull Cancer. 2006;93(8):791-797.
23. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317-328.
24. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343-2246.
25. Landis-Piwowar KR, Huo C, Chen D, et al. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res. 2007;67(9):4303-4310.
26. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263-275.
27. Agrawal A, Gutteridge E, Gee JM, et al. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 2005;12(Suppl 1):S135-S144.
28. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9(Suppl 3):10-15.
29. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630-1639.
30. Lin NU, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004;6(5):204-210.
31. Spector N, Xia W, El-Hariry I, et al. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 2007;9(2):205.
32. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell. 1995;80(2):213-223.
33. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-225.
34. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61(2):203-212.
35. Dawson PJ, Wolman SR, Tait L, et al. MCF10AT: A model for the evolution of cancer from proliferative breast disease. Am J Pathol. 1996;148(1):313-319.
36. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16(7):1647-1655.
37. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100(15):8933-8938.
38. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-354.
39. Berezov A, Chen J, Liu Q, et al. Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem. 2002;277(31):28330-28339.
40. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo-and heterodimers. Mol Cell Biol. 1999;19(10):6845-6857.
41. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319(1):1-11.
42. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12(3):541-552.
43. Garrett TP, McKern NM, Lou M, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell. 2003;11(2):495-505.
44. Ward CW, Garrett TP. Structural relationships between the insulin receptor and epidermal growth factor receptor families and other proteins. Curr Opin Drug Discov Devel. 2004;7(5):630-638.
45. Ciardiello F, Gottardis M, Basolo F, et al. Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol Carcinog. 1992;6(1):43-52.
46. Giunciuglio D, Culty M, Fassina G, et al. Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer. 1995;63(6):815-822.
47. Kokai Y, Myers JN, Wada T, et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 1989;58(2):287-292.
48. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, et al. Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 1998;17(12):3385-3397.
49. Wada T, Qian XL, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 1990;61(7):1339-1347.
50. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits downregulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem. 1999;274(13):8865-8874.
51. DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol. 2005;23(6):1152-1160.
52. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24(2):85-95.
53. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505-516.
54. Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62(14):4132-4141.
55. Chen YN, Mickley LA, Schwartz AM, et al. Characterization of adriamycinresistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem. 1990;265(17):10073-10080.
56. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000;6(9):3739-3747.
57. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000;22(7):673-680.
58. Allison PJ, Nicolau B, Edgar L, et al. Teaching head and neck cancer patients coping strategies: results of a feasibility study. Oral Oncol. 2004;40(5):538-544.
59. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756-760.
60. Ferguson KM. Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans. 2004;32(Pt 5):742-745.
61. Ferguson KM, Berger MB, Mendrola JM, et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell. 2003;11(2):507-517.
62. Hubbard SR. EGF receptor inhibition: Attacks on multiple fronts. Cancer Cell. 2005;7(4):287-288.
63. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301-311.
64. Walker F, Orchard SG, Jorissen RN, et al. CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor. J Biol Chem. 2004;279(21):22387-22398.
65. Ferguson KM, Darling PJ, Mohan MJ, et al. Extracellular domains drive homobut not hetero-dimerization of erbB receptors. EMBO J. 2000;19(17):4632-4643.
66. Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002;110(6):763-773.
67. Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 2002;110(6):775-787.
68. Parra-Palau JL, Morancho B, Peg V, et al. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. J Natl Cancer Inst. 2014;106(11): In press.
69. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628-638.
70. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269-280.
71. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62.